Body and Mind

After a century of false starts, scientists believe they have found a way to make cells burn more energy without the dangerous side effects – and it could be a breakthrough that reshapes weight-loss and anti-aging medicine as we know it.

The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking GLP-1s regain the pounds and return to their original size after 1.7 years. It questions whether we're relying on this "magic cure" too heavily.

A new study from Northwestern University offers hope to Alzheimer's patients and their caregivers. If researchers there are correct, their new small-molecule NU-9 drug may be able to stop the disease long before it begins ruining lives.

Americans are being urged to be extra vigilant, as a new influenza A variant is spreading more rapidly and evading our abilities to fight it off. With more than 110,000 hospitalizations so far, scientists expect this wave to worsen as the season peaks.

In a landmark shift in how mental health conditions are treated in the near future, the US Food and Drug Administration has approved the first at-home brain-stimulation device that can rapidly relieve moderate to severe depression symptoms.

Extracellular vesicles stopped senescence – cellular deterioration in growth and reproduction – by using the extracellular matrix protein fibronectin. The discovery could lead to a method of slowing the aging process.

Magnetic bioactive nanocomposites can eliminate tumors through magnetic arson while helping build new bone. Integrating bioactivity with magnetic performance may be key step in creating smart nanomaterials for oncology and medical regeneration.

ADHD drugs have been thought to sharpen attention, but a new study has found something very different is at play. They don't offer laser-sharp focus but boost wakefulness and engagement, helping the brain stick to tasks it would otherwise give up on.

Coffee is one of the most widely consumed psychoactive substances on the planet, yet despite more than two billion cups being drunk each day, its impact on heart health remains surprisingly complex – and often misunderstood. This year we got answers.

Researchers at Switzerland’s EPFL have created a new neurotherapy that vastly and non-invasively improves vision for patients with hemianopia-related vision loss. Previously, patients suffering from the condition simply had to learn to live with it.

Millions of Americans can now look forward to a better time traveling, with the US Food and Drug Administration approving a novel oral pill that helps prevent motion-induced vomiting – the first of its kind in more than 40 years.

The rise in popularity of GLP-1 receptor agonist drugs like Ozempic is causing a wider societal shift that is now rocking the food industry. And some are feeling the pain more than others, as people make fundamental changes to their lives and health.

Columbia and Stanford researchers have debuted a new paper-thin brain-computer interface, the Biological Interface System to Cortex (BISC). The device offers hope to patients enduring seizures, strokes, spinal cord injuries, ALS, and blindness.

A new MIT method eliminates the need for hour-long infusions of antibodies for immunocompromised patients. With highly concentrated particles of antibodies created without a centrifuge, mass-manufacturing of better single-shot antibodies is here.

An antiviral targeting the dengue virus was quietly abandoned by industry, but it's now suddenly back in the spotlight. A new study suggests it didn’t just slow the dengue virus, it blocked viral replication and reduced infection rates at high doses.